Navigation Links
DarioHealth Closes on $5 Million Through Private Placement Offerings
Date:8/23/2017

CAESAREA, Israel, Aug. 23, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has closed on concurrent private placement offerings with domestic and non-U.S. investors for the sale of shares of the Company's common stock and shares of the Company's newly designated Series B Convertible Preferred Stock in concurrent private placement offerings. Current shareholders accounted for 58% of the securities sold in the offerings. Investors in the offering included existing investors, as well as new investors including SC Fundamental Value Fund, L.P. and Pegasus Capital II, L.P.

As a part of these private placement transactions, which totals $5 million in the aggregate before expenses and placement agent fees, the Company issued 483,333 shares of common stock at a price per share of $1.80 and 2,307,654 shares of Series B Convertible Preferred Stock at a price per share of $1.80. The Series B Preferred Stock is convertible into shares of the Company's common stock at a 1:1 ratio and provides for a 6% dividend payable upon the conversion of the preferred shares. The holders of the Series B Preferred Stock will not be entitled to convert such preferred stock into shares of the Company's common stock until the Company obtains stockholder approval for such issuance. The Company has agreed to file a registration statement covering the resale of the shares of common stock sold in the offering, the shares of common stock underlying the Series B Convertible Preferred Stock and the shares of common stock issuable upon the payment of the dividend, within 60 days of closing. 

The private placement was managed by the Company with the assistance of Aegis Capital Corp., which acted as the placement agent for a portion of the offerings.

Erez Raphael, Chairman and CEO of DarioHealth, commented, "We are very excited with our continued revenue growth trajectory and are confident that our recent Android clearance by the FDA will enable us to accelerate our growth. This additional capital, mainly from existing shareholders and a few long-term fundamental investors that have been monitoring our progress for a few quarters, gives us the extra runway to execute on our strategy to ramp users and reduce our cash burn through the end of 2018. We appreciate the continued support of our existing shareholders and the confidence and trust from our new shareholders."

The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, forward-looking statements are used in this press release when the Company discusses that it is confident that its recent Android clearance will enable it to accelerate its growth and that the funds raised in the offerings gives the Company the extra runway to execute on its strategy to ramp users and reduce its cash burn through the end of 2018. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
="file://10.86.178.61/Users/leah.st/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/6Z27PZHN/shmuel@mydario.com" rel="nofollow" target="_blank">shmuel@mydario.com
+1-914-775-5548

DarioHealth Investor Relations Contact
Hayden IR
Stephen Hart
DRIO@HaydenIR.com 
+1-917-658-7878

 

View original content:http://www.prnewswire.com/news-releases/dariohealth-closes-on-5-million-through-private-placement-offerings-300508346.html


'/>"/>
SOURCE DarioHealth Corp.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. DarioHealth Accelerates U.S. Device Sales and Consumable Strips Growth in Fourth Quarter
2. DarioHealth Corp. to Webcast, Live, at VirtualInvestorConferences.com February 2
3. DarioHealth Reports Fourth Quarter and Year End 2016 Results
4. DarioHealth Corp. Announces Proposed Public Offering of Common Stock
5. DarioHealth Corp. Completes $4.5 Million Public Offering of Common Stock
6. DarioHealth Lowers Diabetes Healthcare Costs in Canada
7. DarioHealth to Present at the 7th Annual LD Micro Invitational
8. DarioHealth to Host Second Quarter Conference Call on August 14, 2017
9. DarioHealth Raises $4.28 Million Through Private Placement Offerings
10. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
11. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):